Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Resumen: Johnson & Johnson obtiene el marcado CE para las lentillas reutilizables ACUVUE OASYS MAX

Thursday, September 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Johnson & Johnson has announced the receipt of CE marking for its new ACUVUE OASYS MAX 2-Week reusable contact lenses. These lenses incorporate patented MAX technologies aimed at providing enhanced comfort and visual clarity for users, even on the 14th day of wear. This approval marks a significant advancement in their product line.

Market Sentiment Analysis

POSITIVE FACTORS

  • Johnson & Johnson received CE marking for ACUVUE OASYS MAX.
  • The lenses are designed for superior comfort and visual clarity.
  • They are reusable and effective even on day 14 of use.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Canagliflozin
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

LIMERICK, Irlanda--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) anunció hoy la obtención del marcado CE para ACUVUE OASYS MAX 2-Week,*** unas nuevas lentillas reutilizables que incluyen las tecnologías patentadas MAX, diseñadas para ofrecer una comodidad y una claridad visual superiores a los pacientes, incluso en el día 14. El comunicado en el idioma original es la versión oficial y autorizada del mismo. Esta traducción es solamente un medio de ayuda y deberá ser comparada con el texto e

Frequently Asked Questions

What is the ACUVUE OASYS MAX?

ACUVUE OASYS MAX is a new line of reusable contact lenses from Johnson & Johnson.

What does CE marking signify?

CE marking indicates that a product meets European safety and health standards.

How long can ACUVUE OASYS MAX lenses be worn?

These lenses are designed for use over a period of two weeks.

What technologies are used in ACUVUE OASYS MAX?

The lenses incorporate patented MAX technologies for enhanced comfort and clarity.

ShareAdd on Google
Tags: JNJ Viatris Investor Conferences Healthcare Johnson & Johnson ACUVUE OASYS MAX CE marking contact lenses visual clarity
Last updated: Sep 10, 2026

Biotech snapshot

Cash runway
$20758M liquidity · $0M/mo burn
Low dilution risk
Lead asset
CanagliflozinPhase 3
Diabetes Mellitus, Type 2 →

Catalyst track record

+34%
best trade around JNJ's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for JNJ.

See every catalyst's timing & PoA →